BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35615557)

  • 1. Genomic Alteration Spectrum of Non-Small Cell Lung Cancer Patients in East-China Characterized by Tumor Tissue DNA and Cell-Free DNA.
    Li J; Chen S; Xue H; Wang H; Huang T; Xie H; He J; Ke C; Yu Z; Ni B
    Onco Targets Ther; 2022; 15():571-584. PubMed ID: 35615557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
    Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
    Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
    Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
    Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Supratentorial Sporadic Hemangioblastoma: A Case Report With Mutation Profiling Using Next-Generation DNA Sequencing.
    Taher MM; Bantan NA; Alwalily MH; Saeed M; Taher NM; Bouzidi M; Jastania RA; Balkhoyour KB
    Cureus; 2023 Jun; 15(6):e39818. PubMed ID: 37273678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Utility of Next-Generation Sequencing in Circulating Free DNA and a Comparison With Matched Tissue in Gallbladder Carcinoma.
    Mishra S; Srivastava P; Pandey A; Shukla S; Agarwal A; Husain N
    Lab Invest; 2024 Feb; 104(2):100301. PubMed ID: 38092180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 7. Characteristics of Genomic Alterations in Pericardial Effusion of Advanced Non-small Cell Lung Cancer.
    He J; Hu X; Chen L; Liu Q; Jiang Y
    Front Genet; 2022; 13():850290. PubMed ID: 35646096
    [No Abstract]   [Full Text] [Related]  

  • 8. Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.
    Liang DH; Ensor JE; Liu ZB; Patel A; Patel TA; Chang JC; Rodriguez AA
    Breast Cancer Res Treat; 2016 Jan; 155(1):139-49. PubMed ID: 26667234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer.
    Cai J; Jiang H; Li S; Yan X; Wang M; Li N; Zhu C; Dong H; Wang D; Xu Y; Xie H; Wu S; Lou J; Zhao J; Li Q
    Front Oncol; 2021; 11():751106. PubMed ID: 35273907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic alteration and PD-L1 expression profiles of Chinese patients with lung squamous cell carcinoma.
    Chen Y; Kong W; Yu Z; Zhao Z
    Pathol Res Pract; 2022 Mar; 231():153761. PubMed ID: 35151031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular features of tumor-derived genetic alterations in circulating cell-free DNA in virtue of autopsy analysis.
    Koba H; Kimura H; Yoneda T; Sone T; Ohkura N; Hara J; Hosomichi K; Tajima A; Kasahara K
    Sci Rep; 2021 Apr; 11(1):8398. PubMed ID: 33863951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Advanced Hepatocellular Carcinoma.
    Cowzer D; White JB; Chou JF; Chen PJ; Kim TH; Khalil DN; El Dika IH; Columna K; Yaqubie A; Light JS; Shia J; Yarmohammadi H; Erinjeri JP; Wei AC; Jarnagin W; Do RKG; Solit DB; Capanu M; Shah RH; Berger MF; Abou-Alfa GK; Harding JJ
    JCO Precis Oncol; 2023 Sep; 7():e2300272. PubMed ID: 37769223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients.
    Keup C; Benyaa K; Hauch S; Sprenger-Haussels M; Tewes M; Mach P; Bittner AK; Kimmig R; Hahn P; Kasimir-Bauer S
    Cell Mol Life Sci; 2020 Feb; 77(3):497-509. PubMed ID: 31254045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of gene mutations and gene-gene fusions in circulating cell-free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis.
    Palande V; Siegal T; Detroja R; Gorohovski A; Glass R; Flueh C; Kanner AA; Laviv Y; Har-Nof S; Levy-Barda A; Viviana Karpuj M; Kurtz M; Perez S; Raviv Shay D; Frenkel-Morgenstern M
    Mol Oncol; 2022 May; 16(10):2098-2114. PubMed ID: 34875133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas.
    Jin Y; Shi X; Zhao J; He Q; Chen M; Yan J; Ou Q; Wu X; Shao YW; Yu X
    Lung Cancer; 2018 Oct; 124():110-116. PubMed ID: 30268447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.
    Jovelet C; Ileana E; Le Deley MC; Motté N; Rosellini S; Romero A; Lefebvre C; Pedrero M; Pata-Merci N; Droin N; Deloger M; Massard C; Hollebecque A; Ferté C; Boichard A; Postel-Vinay S; Ngo-Camus M; De Baere T; Vielh P; Scoazec JY; Vassal G; Eggermont A; André F; Soria JC; Lacroix L
    Clin Cancer Res; 2016 Jun; 22(12):2960-8. PubMed ID: 26758560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study.
    Smyth LM; Reichel JB; Tang J; Patel JAA; Meng F; Selcuklu DS; Houck-Loomis B; You D; Samoila A; Schiavon G; Li BT; Razavi P; Piscuoglio S; Reis-Filho JS; Taylor BS; Baselga J; Solit DB; Hyman DM; Berger MF; Chandarlapaty S
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a Targeted Next-Generation Sequencing Panel for the Non-Invasive Detection of Variants in Circulating DNA of Colorectal Cancer.
    Rodríguez-Casanova A; Bao-Caamano A; Lago-Lestón RM; Brozos-Vázquez E; Costa-Fraga N; Ferreirós-Vidal I; Abdulkader I; Vidal-Insua Y; Rivera FV; Candamio Folgar S; López-López R; Muinelo-Romay L; Diaz-Lagares A
    J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Utility of a Cell-Free DNA Assay in Patients With Colorectal Cancer.
    Chan RH; Lin PC; Chen SH; Lin SC; Chen PC; Lin BW; Shen MR; Yeh YM
    Front Oncol; 2021; 11():589673. PubMed ID: 33816227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort.
    Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Trejo Rosales R; Rojas L; Cruz-Rico G; Nagy R; Cabrera L; Vargas C; Saam J; Barrón F; Arrieta O
    Oncology; 2021; 99(8):539-546. PubMed ID: 33902046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.